Analysis highlights treatment patterns and adherence rates for migraine medications in Japan, suggesting unmet needs remain.
Objective We evaluated real-world treatment patterns and unmet needs associated with migraine preventive medications in Japan following the introduction of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), focusing on persistence, switching, and adherence rates.
No takes yet. Share an insight, caveat, or question.
Takeshima et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: